Search Result

Results for "

Coronary heart disease.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (4) Akt (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (5) Autophagy (1) Biochemical Assay Reagents (1) Calcium Channel (5) CETP (1) Drug Derivative (2) Drug Metabolite (1) Endogenous Metabolite (4) Endothelin Receptor (1) Environmental Pollutants (2) Isotope-Labeled Compounds (2) P-glycoprotein (1) P2Y Receptor (2) p38 MAPK (2) PCSK9 (1) PI3K (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (1) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Scavenger Receptor Class B type I (SR-BI） (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (32) Endocrinology (4) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (1)
Oligonucleotides:	Solvents (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0203

Nebivolol 3 Publications Verification R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-W004284

Heptadecanoic acid 2 Publications Verification	Environmental Pollutants Apoptosis PI3K Akt	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis .

HY-B0642

Isosorbide mononitrate 5 Publications Verification Isosorbide-5-mononitrate	Autophagy Endogenous Metabolite Apoptosis	Cardiovascular Disease Cancer
Isosorbide mononitrate (Isosorbide-5-mononitrate) is an orally active nitric acid compound used for angina pectoris by dilating blood vessels and lowering blood pressure. Isosorbide mononitrate increases the viability and proliferation of HUVECs by decreasing Apoptosis and elevated the expressions of vedf, kdrl, pdgfr in zebrafish embryos. Isosorbide mononitrate is promising for research of heart failure and coronary heart disease .

HY-108750

Soybean oil 1 Publications Verification VT 18 (oil); Vegetoil; Wesson	Environmental Pollutants	Cardiovascular Disease
Soybean oil (VT 18 (oil); Vegetoil; Wesson) is an edible vegetable oil. Soybean oil reduces circulating blood cholesterol levels when it replaces dietary saturated fats. Soybean oil does not affect inflammatory biomarkers or increase oxidative stress. Soybean oil contains γ-tocopherol and δ-tocopherol, which possess antioxidant properties. Soybean oil can be used in research related to coronary heart disease .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-W004284S1

Heptadecanoic acid-d33	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid-d₃₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis .

HY-W004284S

Heptadecanoic acid-d3	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid-d₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis .

HY-N1179

Tanshinone IIB	Apoptosis	Cardiovascular Disease Neurological Disease
Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis .

HY-W004284R

Heptadecanoic acid (Standard)	Reference Standards Apoptosis PI3K Akt	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid (Standard) is the analytical standard of Heptadecanoic acid. This product is intended for research and analytical applications. Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis[1].

HY-N8598

Caulophine	Others	Cardiovascular Disease
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .

HY-107197

8-Prenylchrysin	P-glycoprotein	Cancer
8-prenylchrysin is a C8-prenylated flavonoid. 8-prenylchrysin inhibits P-gp. 8-prenylchrysin can be used for tumor research .

HY-P1536

Thrombin Receptor Activator for Peptide 5 (TRAP-5)	Protease Activated Receptor (PAR)	Cardiovascular Disease
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).

HY-105362

PD 155080	Endothelin Receptor	Cardiovascular Disease
PD 155080 is a selective endothelin A receptor (ET_A receptor) antagonist. PD 155080 reduces coronary resistance in the isolated rat heart model. PD 155080 improves myocardial systolic function and diastolic function in the ischemia/reperfusion model. PD 155080 can be used for the study of cardiovascular diseases .

HY-100418

SKA-111 1 Publications Verification	Potassium Channel	Cardiovascular Disease
SKA-111 is a selective activator of potassium phannel K_Ca3.1 , evokes K_Ca3.1 membrane hyperpolarization in porcine endothelial cell. SKA-111 is capable of improving Bradykinin (HY-P0206)-induced coronary dilations in the isolated rat heart and can be used for cardiovascular disease research .

HY-N4192

Toringin	Others	Cardiovascular Disease Cancer
Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells. Flavonoids are efficacious for ameliorating the RNA gain of function caused by expanded CTG repeats, and have various biological activities and beneficial actions against cancers, coronary heart disease, among other pathologies .

HY-101390D

(R)-Niguldipine	Calcium Channel	Cardiovascular Disease
(R)-Niguldipine, a R-epimer of Niguldipine (HY-101390B), is a calcium channel antagonist. (R)-Niguldipine exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (R)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID₅₀ of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (K_i of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED₃₀ of 5.55). (R)-Niguldipine can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias .

HY-176333

Nebivolol O-β-D-glucuronide	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol O-β-D-glucuronide is a derivative of Nebivolol (HY-B0203). Nebivolol is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0203AR

Nebivolol hydrochloride (Standard) R 065824 hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0130S

Perindopril-d4 erbumine	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Cancer
Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease .

HY-132303

MK-8262	CETP	Cardiovascular Disease Metabolic Disease
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC₅₀ of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .

HY-170774

Hypoxia inducer-1	Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease
Hypoxia inducer-1 (Compound N6) is an orally active hypoxia activated nitric oxide (NO) donor compound. Hypoxia inducer-1 exhibits highly selective NO release under hypoxic conditions and inhibits hypoxia-induced apoptosis, necrosis, and the increase in ROS levels. Hypoxia inducer-1 regulates vascular dilation and has a protective effect in a mouse model of myocardial hypoxia injury. Hypoxia inducer-1 can be used in the research of coronary heart disease .

HY-101390A

(-)-Niguldipine hydrochloride (R)-Niguldipine hydrochloride	Calcium Channel	Cardiovascular Disease
(-)-Niguldipine ((R)-Niguldipine) hydrochloride is a calcium channel antagonist. (-)-Niguldipine hydrochloride exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (-)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID₅₀ of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (K_i of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED₃₀ of 5.55). (-)-Niguldipine hydrochloride can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias .

HY-116295

MRS2690	P2Y Receptor p38 MAPK Calcium Channel	Cardiovascular Disease
MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [ ³⁵S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease .

HY-116295A

MRS2690 disodium	P2Y Receptor p38 MAPK Calcium Channel	Cardiovascular Disease
MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [ ³⁵S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease .

HY-171241

Imolamine	Drug Derivative	Cardiovascular Disease
Imolamine is a potent antiplatelet aggregation agent, is a phenyl aminoxidiazole derivative. Imolamine has the potential for the research of coronary heart disease .

HY-118991

KT-1	Adenosine Receptor	Cardiovascular Disease
KT-1 is a vasodilator. KT 1 can decrease aortic pressure, renal blood flow, left ventricular enddiastolic pressure and resistances of total peripheral, vertebral, coronary and renal vasculatures and increase aortic blood flow, vertebral blood flow, coronary blood flow, peak positive left ventricular dP/dt and heart rate in anesthetized open-chest dogs. KT-1 can be used for the research of cardiovascular disease .

HY-W032902

4-Amino-N-methylphthalimide	Drug Derivative	Cardiovascular Disease
4-Amino-N-methylphthalimide (Compound 13) is an angiogenesis regulator and Thalidomide (HY-14658) derivative. 4-Amino-N-methylphthalimide exerts a bidirectional regulatory (inhibitory or promotive) effect on the proliferation of vascular endothelial cells. 4-Amino-N-methylphthalimide is applicable to the research of coronary heart disease .

HY-106458

Niludipine Bay a 7168	Calcium Channel	Cardiovascular Disease
Niludipine (Bay a 7168) is an orally active calcium channel blocker and vasodilator with antihypertensive effects. Niludipine can improve early fatal ventricular arrhythmias induced by acute myocardial ischemia in rats. Niludipine can reduce left ventricular systolic and diastolic loads during pacing-induced angina pectoris. Niludipine can be used in the research of cardiovascular diseases such as coronary heart disease and myocardial ischemia .

HY-180344

Flurpiridaz	Biochemical Assay Reagents	Cardiovascular Disease
Flurpiridaz is a positron emission tomography (PET) myocardial perfusion imaging tracer. Flurpiridaz can bind to mitochondrial complex I with high affinity. Flurpiridaz demonstrates high heart uptake in multiple species with clear delineation of perfusion deficits. Flurpiridaz shows rapid uptake in the myocardium. Flurpiridaz can be studied in research on coronary artery disease .

HY-182583

PAF antagonist-1	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
PAF antagonist-1 is a platelet activating factor (PAF) receptor antagonist with a target K_i of 69 nM. PAF antagonist-1 inhibits PAF binding and displays enhanced affinity at A₁, A₂ ^a, and A₃ adenosine receptor subtypes compared to related dihydropyridine analogs with smaller ester groups. PAF antagonist-1 can be used for cardiovascular disorders, especially hypertension and coronary heart disease .

HY-133941

2,3-Dinor-6-keto-prostaglandin F1α 2,3-Dinor-6-keto-PGF1α	Drug Metabolite	Cardiovascular Disease
2,3-Dinor-6-keto-prostaglandin F1α (2,3-Dinor-6-keto-PGF1α) is the major urinary metabolite of Prostaglandin I₂ (HY-A0126A). 2,3-Dinor-6-keto-prostaglandin F1α is applicable to the research of coronary heart disease .

HY-120433

BLT-3	Scavenger Receptor Class B type I (SR-BI）	Inflammation/Immunology
BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library	2,282 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,282 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

2,282 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 2,282 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L087

Anti-Obesity Compound Library	3,558 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Type

HY-108750

Soybean oil 1 Publications Verification VT 18 (oil); Vegetoil; Wesson	Biochemical Assay Reagents
Soybean oil (VT 18 (oil); Vegetoil; Wesson) is an edible vegetable oil. Soybean oil reduces circulating blood cholesterol levels when it replaces dietary saturated fats. Soybean oil does not affect inflammatory biomarkers or increase oxidative stress. Soybean oil contains γ-tocopherol and δ-tocopherol, which possess antioxidant properties. Soybean oil can be used in research related to coronary heart disease .

Soybean oil

1 Publications Verification

VT 18 (oil); Vegetoil; Wesson

Biochemical Assay Reagents

Soybean oil (VT 18 (oil); Vegetoil; Wesson) is an edible vegetable oil. Soybean oil reduces circulating blood cholesterol levels when it replaces dietary saturated fats. Soybean oil does not affect inflammatory biomarkers or increase oxidative stress. Soybean oil contains γ-tocopherol and δ-tocopherol, which possess antioxidant properties. Soybean oil can be used in research related to coronary heart disease .

Cat. No.	Product Name	Target	Research Area

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-P1536

Thrombin Receptor Activator for Peptide 5 (TRAP-5)	Protease Activated Receptor (PAR)	Cardiovascular Disease
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W004284

Heptadecanoic acid 2 Publications Verification	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Apoptosis PI3K Akt
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis .

HY-B0642

Isosorbide mononitrate 5 Publications Verification Isosorbide-5-mononitrate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Autophagy Endogenous Metabolite Apoptosis
Isosorbide mononitrate (Isosorbide-5-mononitrate) is an orally active nitric acid compound used for angina pectoris by dilating blood vessels and lowering blood pressure. Isosorbide mononitrate increases the viability and proliferation of HUVECs by decreasing Apoptosis and elevated the expressions of vedf, kdrl, pdgfr in zebrafish embryos. Isosorbide mononitrate is promising for research of heart failure and coronary heart disease .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Endogenous Metabolite
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-N1179

Tanshinone IIB	Cardiovascular Disease Quinones Structural Classification Neurological Disease Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Source Classification	Apoptosis
Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis .

HY-W004284R

Heptadecanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Apoptosis PI3K Akt
Heptadecanoic acid (Standard) is the analytical standard of Heptadecanoic acid. This product is intended for research and analytical applications. Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis[1].

HY-N8598

Caulophine	Alkaloids Caulophyllum robustum Maxim. Plants Berberidaceae Source Classification	Others
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .

HY-N4192

Toringin	Cardiovascular Disease Monophenols Flavonoids other families Classification of Application Fields Flavones Phenols Plants Disease Research Fields Docyniopsis tschonoski Cancer Source Classification	Others
Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells. Flavonoids are efficacious for ameliorating the RNA gain of function caused by expanded CTG repeats, and have various biological activities and beneficial actions against cancers, coronary heart disease, among other pathologies .

HY-133941

2,3-Dinor-6-keto-prostaglandin F1α 2,3-Dinor-6-keto-PGF1α	Structural Classification Endogenous metabolite Lipid Source Classification	Drug Metabolite
2,3-Dinor-6-keto-prostaglandin F1α (2,3-Dinor-6-keto-PGF1α) is the major urinary metabolite of Prostaglandin I₂ (HY-A0126A). 2,3-Dinor-6-keto-prostaglandin F1α is applicable to the research of coronary heart disease .

Cat. No.	Product Name	Chemical Structure

HY-W004284S1

Heptadecanoic acid-d33
Heptadecanoic acid-d₃₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis .

HY-W004284S

Heptadecanoic acid-d3
Heptadecanoic acid-d₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis .

HY-B0130S

Perindopril-d4 erbumine
Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease .

Cat. No.	Product Name		Classification

HY-108750

Soybean oil 1 Publications Verification VT 18 (oil); Vegetoil; Wesson		Solvents
Soybean oil (VT 18 (oil); Vegetoil; Wesson) is an edible vegetable oil. Soybean oil reduces circulating blood cholesterol levels when it replaces dietary saturated fats. Soybean oil does not affect inflammatory biomarkers or increase oxidative stress. Soybean oil contains γ-tocopherol and δ-tocopherol, which possess antioxidant properties. Soybean oil can be used in research related to coronary heart disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Coronary heart disease.

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products